Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514195 | 0.88 | ADORA3 (0.48) | ADORA3TDP1 | |
| SCHEMBL13936982 | 0.86 | ADORA3 (0.48) | ADORA3TDP1KDM4E | |
| SCHEMBL4515441 | 0.86 | ADORA3 (0.53) | ADORA3KDM4E | |
| SCHEMBL4494247 | 0.83 | L3MBTL1 (0.50) | KDM4E | |
| SCHEMBL21023408 | 0.81 | ADORA3 (0.41) | ADORA3 | |
| SCHEMBL4504538 | 0.80 | ALDH1A1 (0.47) | ADORA3KDM4E | |
| SCHEMBL14403955 | 0.79 | TP53 (0.41) | KDM4E | |
| SCHEMBL13936980 | 0.77 | KMO (0.39) | ADORA3 | |
| SCHEMBL4503621 | 0.77 | NPC1 (0.45) | ADORA3 | |
| SCHEMBL4502999 | 0.76 | HCAR2 (0.47) | ADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | AJINOMOTO CO., INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1318147-A1 | NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | ADORA3 102/4885TDP1 1551/4885KDM4E 3546/4885 |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | CACNA1I, CACNA1B, CACNA1E | ADORA3 107/4885TDP1 1248/4885KDM4E 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.